1
|
Yang HY, Fierro F, So M, Yoon DJ, Nguyen AV, Gallegos A, Bagood MD, Rojo-Castro T, Alex A, Stewart H, Chigbrow M, Dasu MR, Peavy TR, Soulika AM, Nolta JA, Isseroff RR. Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice. Stem Cells Transl Med 2020; 9:1353-1364. [PMID: 32720751 DOI: 10.1002/sctm.19-0380] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 05/21/2020] [Accepted: 06/10/2020] [Indexed: 12/17/2022] Open
Abstract
Diabetic foot ulcers are a major health care concern with limited effective therapies. Mesenchymal stem cell (MSC)-based therapies are promising treatment options due to their beneficial effects of immunomodulation, angiogenesis, and other paracrine effects. We investigated whether a bioengineered scaffold device containing hypoxia-preconditioned, allogeneic human MSCs combined with the beta-adrenergic antagonist timolol could improve impaired wound healing in diabetic mice. Different iterations were tested to optimize the primary wound outcome, which was percent of wound epithelialization. MSC preconditioned in 1 μM timolol at 1% oxygen (hypoxia) seeded at a density of 2.5 × 105 cells/cm2 on Integra Matrix Wound Scaffold (MSC/T/H/S) applied to wounds and combined with daily topical timolol applications at 2.9 mM resulted in optimal wound epithelialization 65.6% (24.9% ± 13.0% with MSC/T/H/S vs 41.2% ± 20.1%, in control). Systemic absorption of timolol was below the HPLC limit of quantification, suggesting that with the 7-day treatment, accumulative steady-state timolol concentration is minimal. In the early inflammation stage of healing, the MSC/T/H/S treatment increased CCL2 expression, lowered the pro-inflammatory cytokines IL-1B and IL6 levels, decreased neutrophils by 44.8%, and shifted the macrophage ratio of M2/M1 to 1.9 in the wound, demonstrating an anti-inflammatory benefit. Importantly, expression of the endothelial marker CD31 was increased by 2.5-fold with this treatment. Overall, the combination device successfully improved wound healing and reduced the wound inflammatory response in the diabetic mouse model, suggesting that it could be translated to a therapy for patients with diabetic chronic wounds.
Collapse
Affiliation(s)
- Hsin-Ya Yang
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Fernando Fierro
- Department of Cell Biology and Human Anatomy, University of California, Davis, Sacramento, California, USA.,Stem Cell Program, Department of Internal Medicine, University of California, Davis, Davis, California, USA
| | - Michelle So
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Daniel J Yoon
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Alan Vu Nguyen
- Department of Dermatology, University of California, Davis, Sacramento, California, USA.,Institute for Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA
| | - Anthony Gallegos
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Michelle D Bagood
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Tomas Rojo-Castro
- Department of Biological Sciences, California State University, Sacramento, Sacramento, California, USA
| | - Alan Alex
- Department of Biological Sciences, California State University, Sacramento, Sacramento, California, USA
| | - Heather Stewart
- Stem Cell Program, Department of Internal Medicine, University of California, Davis, Davis, California, USA
| | - Marianne Chigbrow
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Mohan R Dasu
- Department of Dermatology, University of California, Davis, Sacramento, California, USA
| | - Thomas R Peavy
- Department of Biological Sciences, California State University, Sacramento, Sacramento, California, USA
| | - Athena M Soulika
- Department of Dermatology, University of California, Davis, Sacramento, California, USA.,Institute for Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA
| | - Jan A Nolta
- Stem Cell Program, Department of Internal Medicine, University of California, Davis, Davis, California, USA
| | - R Rivkah Isseroff
- Department of Dermatology, University of California, Davis, Sacramento, California, USA.,Dermatology Section, VA Northern California Health Care System, Mather, California, USA
| |
Collapse
|
2
|
Woller S, Ravula S, Tucci F, Beaton G, Corr M, Isseroff R, Soulika A, Chigbrow M, Eddinger K, Yaksh T. Corrigendum to "Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state" [Brain Behav. Immun. 56 (2016) 271-280]. Brain Behav Immun 2018; 69:632. [PMID: 29291934 PMCID: PMC6814394 DOI: 10.1016/j.bbi.2017.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- S.A. Woller
- University of California, San Diego, 9500 Gilman Drive, La
Jolla, CA 92093-0818, USA
| | - S.B. Ravula
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite
A104, San Diego, CA 92121, USA
| | - F.C. Tucci
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite
A104, San Diego, CA 92121, USA
| | - G. Beaton
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite
A104, San Diego, CA 92121, USA
| | - M. Corr
- University of California, San Diego, 9500 Gilman Drive, La
Jolla, CA 92093-(0663), USA
| | - R.R. Isseroff
- University of California, Davis, 3301 C Street, Suite 1400,
Sacramento, CA 95816-3367, USA
| | - A.M. Soulika
- University of California, Davis, Shriners Hospital,
Northern California, 2425 Stockton Boulevard, Research 631A, Sacramento, CA
95817-2215, USA
| | - M. Chigbrow
- University of California, Davis, 3301 C Street, Suite 1400,
Sacramento, CA 95816-3367, USA
| | - K.A. Eddinger
- University of California, San Diego, 9500 Gilman Drive, La
Jolla, CA 92093-0818, USA
| | - T.L. Yaksh
- University of California, San Diego, 9500 Gilman Drive, La
Jolla, CA 92093-0818, USA,Corresponding author.
(T.L. Yaksh)
| |
Collapse
|
3
|
Woller SA, Ravula SB, Tucci FC, Beaton G, Corr M, Isseroff RR, Soulika AM, Chigbrow M, Eddinger KA, Yaksh TL. Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state. Brain Behav Immun 2016; 56:271-80. [PMID: 27044335 PMCID: PMC4917460 DOI: 10.1016/j.bbi.2016.03.026] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 03/22/2016] [Accepted: 03/31/2016] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVE Pain resulting from local tissue injury or inflammation typically resolves with time. Frequently, however, this pain may unexpectedly persist, becoming a pathological chronic state. Increasingly, the innate and adaptive immune systems are being implicated in the initiation and maintenance of these persistent conditions. In particular, Toll-like receptor 4 (TLR4) signaling has been shown to mediate the transition to a persistent pain state in a sex-dependent manner. In the present work, we explored this contribution using the TLR4 antagonist, TAK-242. METHODS Male and female C57Bl/6 mice were given intravenous (IV), intrathecal (IT), or intraperitoneal (IP) TAK-242 prior to IT delivery of lipopolysaccharide (LPS), and tactile reactivity was assessed at regular intervals over 72-h. Additional groups of mice were treated with IP TAK-242 prior to intraplantar formalin, and flinching was monitored for 1-h. Tactile reactivity was assessed at 7-days after formalin delivery. RESULTS LPS evoked TNF release from male and female macrophages and RAW267.4 cells, which was blocked in a concentration dependent fashion by TAK-242. In vivo, IT LPS evoked tactile allodynia to a greater degree in male than female mice. TAK-242, given by all routes, prevented development of IT LPS-induced tactile allodynia in male animals, but did not reverse their established allodynia. TLR4 deficiency and TAK-242 treatment attenuated IT LPS-induced allodynia in male, but not female mice. In the formalin model, pre-treatment with TAK-242 did not affect Phase 1 or Phase 2 flinching, but prevented the delayed tactile allodynia in both male and unexpectedly in female mice (Phase 3). CONCLUSIONS Together, these results suggest that TAK-242 is a TLR4 antagonist that has efficacy after systemic and intrathecal delivery and confirms the role of endogenous TLR4 signaling in triggering the development of a delayed allodynia in both male and female mice.
Collapse
Affiliation(s)
- Sarah A Woller
- Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA; Department of Medicine, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, USA.
| | - Satheesh B Ravula
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite A104, San Diego, CA 92121, USA.
| | - Fabio C Tucci
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite A104, San Diego, CA 92121, USA.
| | - Graham Beaton
- Epigen Biosciences Inc., 10225 Barnes Canyon Road, Suite A104, San Diego, CA 92121, USA.
| | - Maripat Corr
- Department of Medicine, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, USA.
| | - R Rivkah Isseroff
- Department of Dermatology, School of Medicine, University of California, Davis, CA, USA.
| | - Athena M Soulika
- Department of Dermatology, School of Medicine, University of California, Davis, CA, USA; Shriners Hospital for Children, Northern California, Sacramento, CA, USA.
| | - Marianne Chigbrow
- Department of Dermatology, School of Medicine, University of California, Davis, CA, USA.
| | - Kelly A Eddinger
- Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.
| | - Tony L Yaksh
- Department of Anesthesiology, University of California San Diego, La Jolla, CA, USA.
| |
Collapse
|
4
|
Goulet AC, Chigbrow M, Frisk P, Nelson MA. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 2004; 26:109-17. [PMID: 15513932 DOI: 10.1093/carcin/bgh306] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Selenomethionine (SeMet) is being tested alone and in combination with other agents in cancer chemoprevention trials. However, the molecular targets and the signaling mechanism underlying the anticancer effect of this compound are not completely clear. Here, we provide evidence that SeMet can induce cell-growth arrest and that the growth inhibition is associated with S-G2/M cell-cycle arrest. Coincidentally with the cell-cycle arrest, we observed a striking increase in cyclin B as well as phosphorylation of the cyclin-dependent kinase Cdc2. Since activation of the mitogen-activated protein kinase (MAPK) cascade has been associated with cell-cycle arrest and growth inhibition, we evaluated the activation of extracellular signal-regulated kinase (ERK). We found that SeMet induced phosphorylation of the MAPK ERK in a dose-dependent manner. We also demonstrate phosphorylation of ribosomal S6 kinase (p90RSK) by SeMet. Additionally, we show phosphorylation of histone H3 in a concentration-dependent manner. Furthermore, the phosphorylation of p90RSK and histone H3 were both antagonized by the MEK inhibitor U0126, implying that SeMet-induced phosphorylation of p90RSK and histone H3 are at least in part ERK pathway dependent. Based on these results, we propose that SeMet induced growth arrest and phosphorylation of histone H3 are mediated by persistent ERK and p90RSK activation. These new data provide valuable insights into the biological effects of SeMet at clinically relevant concentrations.
Collapse
Affiliation(s)
- Anne-Christine Goulet
- Department of Pathology, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
| | | | | | | |
Collapse
|